Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens.
The first and only FDA-cleared panel that detects Pneumocystis jirovecii in addition to a broad spectrum of clinically relevant bacterial pathogens and antibiotic resistance markers associated with pneumonia.
The FDA-cleared Unyvero Lower Respiratory Tract infection panels help you quickly optimize antibiotic therapy.
Detect the largest number of relevant pathogens and resistance markers*
Deliver rapid, reliable, and actionable answers
Enable earlier diagnosis and selection of optimal treatment
Unyvero LRT panels uniquely detect the most clinically relevant pathogens and resistance markers, including the broadest carbapenemase resistance coverage.*
For clear, comprehensive, and reliable results to advance antimicrobial stewardship initiatives, Unyvero points the way.
* Compared to other molecular panels.
The Unyvero Solution
Pathogen identification and resistance reported in just a matter of hours, using multiplex PCR technology
Excellent sensitivity and specificity with no growth required for detection of organisms and resistance genes, and results are not impacted by prior antibiotic use
Rapid detection of clinically relevant targets enables earlier optimal antibiotic decision
Enables testing during all microbiology laboratory shifts with an automated sample-to-answer process that drives results directly from specimen
What can Unyvero mean to you?
Need to identify the pathogen and resistance quickly.
Need to know the cause to implement the right treatment plan.
Need to prescribe appropriate antibiotics for effective treatment.
Need to control healthcare costs, increase DRG yield and improve ROI.